Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.psychres.2015.05.105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between the Taq1A polymorphism and problematic media use in preadolescent children.
Front Psychol
January 2025
Department of Pediatrics, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States.
Objective: Problematic media use (PMU) is addiction-like media use. No study has examined if genetic factors for addiction relate to PMU during childhood. This study tested the association between genetic risk factors for addiction and PMU among 9-to-12-year-olds.
View Article and Find Full Text PDFPharmacogenetic Testing in Treatment-resistant Panic Disorder: a Preliminary Analysis.
Clin Pract Epidemiol Ment Health
December 2024
Laboratory of Panic and Respiration, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro, RJ, Brazil.
Background: Many pharmacological treatments are considered effective in the treatment of panic disorder (PD), however, about 20 to 40% of the patients have treatment-resistant PD. Pharmacogenetics could explain why some patients are treatment-resistant.
Objective: Our objective was to gather preliminary data on the clinical usefulness of pharmacogenetic testing in this disorder.
Inhibition of mPFC norepinephrine improved chronic post-thoracotomy pain in adult rats.
Ann Med
December 2025
Department of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Background: Chronic post-thoracotomy pain (CPTP) is characterized by high incidence, long duration, and severity of pain. Medial prefrontal cortex (mPFC) is a brain region closely associated with chronic pain, and norepinephrine is involved in pain regulation. But the role of mPFC norepinephrine in CPTP and its possible mechanism is unclear.
View Article and Find Full Text PDFComparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies.
Clin Neuropharmacol
January 2025
MedStar Georgetown University Hospital, Washington, DC.
Introduction: Adjunctive therapies to treat OFF episodes resulting from long-term levodopa treatment in Parkinson disease (PD) are hampered by safety and tolerability issues. Istradefylline offers an alternative mechanism (adenosine A2A receptor antagonist) and therefore potentially improved tolerability.
Methods: A systematic review of PD adjuncts published in 2011 was updated to include randomized controlled trials published from January 1, 2010-April 15, 2019.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!